Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -8.4x - -9.3x | -8.8x |
| Selected Fwd P/E Multiple | -9.2x - -10.2x | -9.7x |
| Fair Value | $26.41 - $29.19 | $27.80 |
| Upside | -22.0% - -13.8% | -17.9% |
| Benchmarks | - | Full Ticker |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Trevena, Inc. | - | OTCPK:TRVN |
| BridgeBio Pharma, Inc. | - | NasdaqGS:BBIO |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| DYAI | ONCO | CRDF | GERN | TRVN | BBIO | |||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | NasdaqGS:BBIO | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 14.5% | -182.3% | -9.6% | 5.2% | -10.6% | 16.7% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -404.2% | -19098.5% | -7594.3% | -23982.0% | -19680.3% | -2361.4% | ||
| Prior Fiscal Year | -234.4% | NA | -8496.9% | -77690.7% | 12839.7% | -6913.9% | ||
| Latest Fiscal Year | -166.2% | -63986.5% | -6655.2% | -226.7% | -1289.2% | -241.4% | ||
| Latest Twelve Months | -166.2% | -2758.7% | -6655.2% | -226.7% | -6233.7% | -241.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | NA | -1.3x | -2.2x | -2.4x | -0.8x | -13.2x | ||
| Price / LTM Sales | 10.7x | 0.3x | 286.4x | 10.3x | 1.8x | 29.0x | ||
| LTM P/E Ratio | -6.4x | 0.0x | -4.3x | -4.6x | 0.0x | -12.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -6.4x | -4.3x | 0.0x | |||||
| Historical LTM P/E Ratio | -21.7x | -11.5x | -2.3x | |||||
| Selected P/E Multiple | -8.4x | -8.8x | -9.3x | |||||
| (x) LTM Net Income | (536) | (536) | (536) | |||||
| (=) Equity Value | 4,502 | 4,739 | 4,976 | |||||
| (/) Shares Outstanding | 190.2 | 190.2 | 190.2 | |||||
| Implied Value Range | 23.67 | 24.92 | 26.16 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 23.67 | 24.92 | 26.16 | 33.85 | ||||
| Upside / (Downside) | -30.1% | -26.4% | -22.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | BBIO | |
| Value of Common Equity | 37 | 0 | 187 | 790 | 1 | 6,438 | |
| (/) Shares Outstanding | 30.1 | 8.3 | 66.5 | 636.9 | 0.9 | 190.2 | |
| Implied Stock Price | 1.24 | 0.06 | 2.81 | 1.24 | 1.18 | 33.85 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.24 | 0.06 | 2.81 | 1.24 | 1.18 | 33.85 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |